Non-Hodgkin's Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma (DLBCL); DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements; Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma; LBCL With IRF4 Rearrangement; High-grade B-cell Lymphoma With 11q Aberration; Epstein-Barr Virus-Positive DLBCL; DLBCL Associated With Chronic Inflammation; Fibrin-associated LBCL; Primary Cutaneous DLBCL, Leg Type; Intravascular LBCL; Primary Mediastinal LBCL; High-grade B-cell Lymphoma; DLBCL Arising From Transformed Indolent Lymphoma; Mediastinal Gray Zone Lymphoma; FL Grade 3B; MCL Interventions: ...
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Non-Hodgkin Lymphoma Interventions: Drug: Rocbrutinib; Biological: Rituximab; Drug: Cyclophosphamide; Drug: doxorubicin; Drug: Vincristin; Drug: Prednisone Sponsors: Guangzhou Lupeng Pharmaceutical Company LTD. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Conditions: B-Cell Non-Hodgkin Lymphoma Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Biological: Pembrolizumab; Procedure: Positron Emission Tomography; Drug: Tazemetostat Sponsors: Northwestern University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Primary Mediastinal Large B-Cell Lymphoma; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Epcoritamab; Procedure: Magnetic Resonance Imaging; Other: Patient Observation; Procedure: Positron Emission Tomography Sponsors: Academic and Community Cancer Research United Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL) Interventions: Drug: Odronextamab; Drug: Ifosfamide; Drug: Carboplatin; Drug: Etoposide; Drug: Rituximab; Drug: Dexamethasone; Drug: Cisplatin; Drug: Cytarabine; Drug: Gemcitabine Sponsors: Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Conditions: Non-Hodgkin Lymphoma Interventions: Drug: GLB-002 Sponsors: Hangzhou GluBio Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

This Phase I/II Trial Assesses Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphomas (PMBCL/CNS-BCL). It Explores Safety, Efficacy, and Simplifying Cell Production, Enrolling Patients From Multiple Centers
Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCL Interventions: Biological: CD19/CD22-CAR T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin Lymphoma, B-cell; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma; Lymphoma, Follicular; MCL Interventions: Biological: CD19/CD22-CAR T cells Sponsors: Essen Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
Conditions: Lymphoma, B-Cell; CAR-T Interventions: Biological: C752 Sponsors: 920th Hospital of Joint Logistics Support Force of People ' s Liberation Army of China; Shanghai PerHum Therapeutics Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma Interventions: Procedur...
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Conditions: B-Cell Leukemia; Non-Hodgkin ' s Lymphoma; B-cell Acute Lymphoblastic Leukemia; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma (PMBCL); Mantle Cell Lymphoma; B-cell Lymphoma Interventions: Biological: CLIC-2201 Sponsors: British Columbia Cancer Agency Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Conditions: Non-Hodgkin ' s Lymphoma Interventions: Drug: After preconditioning with chemotherapy, F01 will be evaluated. Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Conditions: Hematologic Malignancy; Non Hodgkin Lymphoma; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia, Adult; Myelodysplastic Syndromes Interventions: Drug: TGRX-814 Sponsors: Shenzhen TargetRx, Inc.; Institute of Hematology& Blood Diseases Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

The Pathogenesis and Prognostic Factors of Lymphoma
Conditions: Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma Interventions: Other: Real-world regimen Sponsors: Shanghai Zhongshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Conditions: B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia Interventions: Biological: Autologous BAFFR-tar...
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials